Can predictive analytics help reduce hospital-acquired infections?
A biotech entrepreneur wants to give physicians an electronic companion tool to help hospitals help fight and reduce hospital acquired infections.
In 2013 antibiotic resistant infections caused more than two million illnesses and over 23,000 deaths in the US alone, according to the Centers for Disease control. Around 70% of those infections were found to have come from hospital acquired infections.
Normally after taking a culture it can take two to four days for a result to be found. The company wants to shorten that and also figure out the patient’s resistance profile to ensure that physicians prescribe the most effective drug for each patient.
Lumincare solutions have come up with a platform technology that combines biotech and big data. It uses predictive modelling analytics to diagnose hospital-acquired infections faster and determine the level of resistance for drug-resistant bacterial infections. The company is also one of the latest editions to StartUP Health’s portfolio.
LuminaCare Solutions CEO David Howe, who has had family members contract bacterial infections. He began studying the issue of antibiotic resistance mechanisms in-depth when he pursued a PhD at University of Michigan before working in the pharmaceutical industry for Vertex Pharmaceuticals and AstraZeneca.
“When you look at what’s happening with patients it’s pretty much a black box for physicians as far as determining whether the bacteria is resistant or not..and what’s the appropriate dosage,” said Howe.
The platform technology processes the results of a PCR test as well as processing antibiotic information and data points around bacteria. The company’s platform straddles infectious disease, clinical pharmacology and epidemiology into an interface for coordinated care.
Howe said that the company is still in very early stages and that there is a lot more work to be done before this technology will be seen in hospitals however the news of this technology is very positive and side projects such as an application for pharmaceutical companies to assess patients resistance profiles for clinical trial recruitment has also been considered.